University Hospital
Clifford Bridge Road
Walsgrave
Coventry
CV2 2DX

Direct Line: 024 76968771
www.uhcw.nhs.uk

Dear Requester

We acknowledge receipt of your email to UHCW:

Freedom of Information Request Form

If you have submitted a request under the Freedom of Information Act
(FOIA) your request will be considered and you will receive our response
within the statutory timescale of 20 working days.

The reference number for your email is FOI/2057.

Should you have any further inquiries concerning this matter, please reply
to this email leaving the subject line unchanged.

Yours sincerely,
UHCW

 
University Hospital
Clifford Bridge Road
Walsgrave
Coventry
CV2 2DX

Direct Line: 024 76968771
www.uhcw.nhs.uk

Our Ref: FOI/2057
Date: 29th September 2022

By email only

Dear Requester

We write further to your request for information under the Freedom of
Information Act received 31st August 2022.  We have set out your request,
together with our response below. 

Q1. In the past 3 months (or the latest 3 months data you have available),
how many Metastatic/advanced Breast cancer patients were treated with:
• Abemaciclib (Verzenios) + aromatase inhibitor * - 1-10
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex) - 11
• Alpelisib (Piqray) + Fulvestrant (Faslodex) - 1-10
• Atezolizumab (Tecentriq)**- 1-10
• Bevacizumab (Avastin) - 0
• Eribulin (Halaven) - 20
• Everolimus (Afinitor) + Exemestane - 1-10
• Fulvestrant (Faslodex) as a single agent - 49
• Gemcitabine + paclitaxel - 1-10
• Herceptin (Trastuzumab) + paclitaxel - 1-10
• Herceptin (Trastuzumab) as a single agent - 0
• Lapatinib (Tyverb) - 0
• Neratinib (Nerlynx) - 1-10
• Olaparib (Lynparza) - 0
• Palbociclib (Ibrance) + aromatase inhibitor* - 89
• Palbociclib (Ibrance) + Fulvestrant (Faslodex) - 16
• Pertuzumab (Perjeta) + trastuzumab + docetaxel - 1-10
• Ribociclib (Kisqali) + aromatase inhibitor* - 1-10
• Ribociclib (Kisqali) + Fulvestrant (Faslodex) - 0
• Talazoparib (Talzenna) - 0
• Trastuzumab emtansine (Kadcyla) - 48
• Other active systemic anti-cancer therapy ** - 0
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever
dose for each product line?

• Abemaciclib (Verzenios) + aromatase inhibitor *  - 1-10
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex) - 0
• Alpelisib (Piqray) + Fulvestrant (Faslodex) - 1-10
• Atezolizumab (Tecentriq)** - 0
• Bevacizumab (Avastin) - 0
• Eribulin (Halaven) - 1-10
• Everolimus (Afinitor) + Exemestane - 0
• Fulvestrant (Faslodex) as a single agent - 16
• Gemcitabine + paclitaxel - 0
• Herceptin (Trastuzumab) + paclitaxel - 0
• Herceptin (Trastuzumab) as a single agent - 0
• Lapatinib (Tyverb) - 0
• Neratinib (Nerlynx) - 0
• Olaparib (Lynparza) - 0
• Palbociclib (Ibrance) + aromatase inhibitor* - 16
• Palbociclib (Ibrance) + Fulvestrant (Faslodex) - 1-10
• Pertuzumab (Perjeta) + trastuzumab + docetaxel - 1-10
• Ribociclib (Kisqali) + aromatase inhibitor* - 0
• Ribociclib (Kisqali) + Fulvestrant (Faslodex) - 0
• Talazoparib (Talzenna) - 0
• Trastuzumab emtansine (Kadcyla) - 12

Please note that due to the availability of inferred or derived
information from other sources, there may be a risk of identification
owing to the very low numbers involved. For this reason, we are only able
to provide you with aggregated answers.

As we have provided the information that we do hold your request is now
closed.  We trust that this is satisfactory but if you are dissatisfied
with the way that it has been handled you have the right to ask for an
internal review.  Internal review requests should be submitted within two
months of the date of receipt of the response to your original letter and
should be addressed to: David Walsh, Director of Corporate Affairs,
University Hospitals Coventry & Warwickshire NHS Trust, Clifford Bridge
Road, Coventry CV2 2DX.

If you are not content with the outcome of the internal review, you have
the right to apply directly to the Information Commissioner for a
decision.  The Information Commissioner can be contacted at: Information
Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9
5AF.

Yours sincerely

Andrea Phillips
FOI & Access to Health Records Manager